Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

icon1
USD 10.92 BN
MARKET SIZE, 2035
icon2
CAGR 13.2%
(2025-2035)
icon3
445
REPORT PAGES
icon4
420
MARKET TABLES

OVERVIEW

radioligand-therapy-rlt-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global radioligand therapy market is estimated to be USD 3.15 billion in 2025 and reach USD 10.91 billion by 2035, with a CAGR of 13.2% during the forecast period. The radioligand therapy market is expected to accelerate due to the increasing prevalence of cancer and a robust pipeline of radioligand therapeutics.

KEY TAKEAWAYS

  • By Region
    The North America peptide synthesis market accounted for a 75.8% revenue share in 2024.
  • By Product
    By Product, the Lutetium-177 vipivotide tetraxetan (Pluvicto) segment is expected to register the highest CAGR of 5%.
  • By Target
    By Target, the Prostate-Specific Membrane Antigen segment will grow the fastest during the forecast period.
  • By Indication
    By indication, the prostate cancer segment is expected to dominate the market, growing at the highest CAGR of 13.7%.
  • competitive landscape
    Novartis , Bayer AG and Eli Lilly & Co. were identified as some of the star players in the cell counting market (global), given their strong market share and product footprint.

The radioligand therapy (RLT) market is undergoing rapid transformation driven by technological advancements, regulatory progress, and evolving business models. A significant shift toward alpha-emitting therapies such as actinium-225 and lead-212, which deliver highly potent and localized radiation, offering greater efficacy with reduced toxicity compared to traditional beta emitters. Companies invest in next-generation ligand design to improve tumor specificity, enhance stability, and enable combination therapies with immuno-oncology agents

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The radioligand therapy (RLT) market is undergoing significant transformation driven by the rapid expansion of targeted radionuclide therapies and growing adoption of theranostic approaches. Rising complexity in isotope supply, increasing demand for precision oncology, and the need for GMP-compliant radiopharmaceutical manufacturing are accelerating the shift toward specialized radioligand production partners. At the same time, evolving regulatory expectations for nuclear safety, radiation handling, and cross-border isotope logistics are reshaping operational frameworks for suppliers and treatment centers. Technology disruptions such as automated radiochemistry modules, advanced isotope purification, decentralized manufacturing models, and AI-enhanced imaging are enabling faster synthesis, higher product reliability, and reduced radiation exposure risk. These developments are pushing oncology networks and pharma companies toward integrated RLT manufacturing ecosystems, driving demand for next-generation radioligand production, quality, and supply-chain capabilities.

radioligand-therapy-rlt-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing approvals and label expansion of RLT products
  • Manufacturing scale-up of Lu-177
RESTRAINTS
Impact
Level
  • Isotope supply scarcity
  • Stringent regulatory requirements
OPPORTUNITIES
Impact
Level
  • Advancements in alpha therapies
  • Expansion of radioligand therapy into earlier-line and adjuvant settings
CHALLENGES
Impact
Level
  • Reactor outages and geopolitical risks
  • Growing competition from alternative modalities

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver:Increasing approvals and label expansion of RLT products

Increasing approvals and label expansions of radioligand therapy (RLT) products are accelerating market growth by validating clinical efficacy across new cancer types and expanding eligible patient populations. As leading therapies gain broader indications, demand rises for isotope supply, GMP radiopharmaceutical production, and specialized treatment infrastructure, strengthening commercial adoption.

Restraint: Isotope supply scarcity

Isotope supply scarcity is a significant restraint for the radioligand therapy (RLT) market. Limited global production of critical isotopes such as Lu-177 and Ac-225, dependence on a small number of reactors, and complex logistics create supply bottlenecks. These constraints hinder manufacturing scalability, delay treatment availability, and increase production costs, slowing broader market adoption.

Opportunity: Advancements in alpha therapies

Advancements in alpha therapies present a major opportunity for the radioligand therapy market. Highly potent alpha-emitting isotopes such as Ac-225 and Pb-212 offer superior tumor-killing efficiency with minimal off-target toxicity. Growing R&D investment, improved production methods, and expanding clinical pipelines position alpha therapies to drive next-generation RLT innovation and market expansion.

Challenge: Reactor outages and geopolitical risks

Reactor outages and geopolitical risks pose a significant challenge to the radioligand therapy market. Unplanned shutdowns of nuclear reactors, export restrictions, and reliance on a limited number of isotope-producing countries disrupt the supply of critical medical isotopes such as Lu-177 and Ac-225. These vulnerabilities create supply instability, increase production costs, and delay treatment availability for patients.

radioligand-therapy-rlt-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Novartis partners with ITM Isotope Technologies Munich for large-scale supply of Lutetium-177 (Lu-177) used in Pluvicto (PSMA-targeted therapy) and Lutathera (NET therapy).. Ensures uninterrupted isotope availability for global RLT rollout; strengthens long-term supply chain resilience for high-demand oncology therapies
Bayer collaborates with Eckert & Ziegler to secure Actinium-225 and Gallium-68 supply for expanding its alpha-emitter RLT pipeline targeting prostate and lung cancers.. Access to scalable alpha therapy isotope supply and accelerated development of next-generation RLT candidates..
Telix partners with Cardinal Health for US nationwide radiopharmacy manufacturing and distribution of Illuccix (Ga-68 PSMA imaging agent) used prior to Lu-177 PSMA therapy. Rapid same-day PET agent delivery; expanded reach to thousands of imaging sites, improving treatment eligibility and patient throughput.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The radioligand therapy (RLT) market ecosystem consists of isotope producers (ITM, Eckert & Ziegler), radiopharmaceutical manufacturers (Novartis, Curium), and specialized CDMOs offering radionuclide production, conjugation, aseptic filling, and final dose manufacturing. These players support oncology drug developers, hospitals, nuclear medicine centers, and academic institutions with end-to-end services ranging from isotope supply to GMP radioligand production. Market demand is driven by the expanding pipeline of beta and alpha emitters, rising clinical adoption in prostate and neuroendocrine tumors, and growing interest from biotech companies entering targeted radiotherapeutics. Collaboration across isotope suppliers, radiopharm CDMOs, cyclotron operators, and therapy providers enables advancements in generator technology, automated synthesis modules, cold-chain logistics, and regulatory compliance. This integration supports the market’s evolution toward scalable, reliable, and high-precision radioligand manufacturing solutions.

radioligand-therapy-rlt-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

radioligand-therapy-rlt-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Radioligand Therapy Market, By Product

As of 2024, Lutetium-177 vipivotide tetraxetan (Pluvicto) accounts for the largest share of the radioligand therapy market and is expected to maintain its lead through 2025. Its dominance is driven by strong clinical efficacy in metastatic castration-resistant prostate cancer, rapid global uptake, and expanding commercial availability. Unlike pipeline RLTs, Pluvicto benefits from established manufacturing, regulatory approvals, and growing physician adoption, creating sustained demand. Ongoing clinical trials exploring earlier-line use and label expansion further reinforce Pluvicto as the primary revenue-generating product in the radioligand therapy market

Radioligand Therapy Market, By Target

As of 2024, prostate-specific membrane antigen (PSMA)–targeted radioligand therapies hold the largest share of the radioligand therapy market and are expected to maintain this lead through 2025. This dominance is driven by the high prevalence of advanced prostate cancer, strong clinical outcomes of PSMA-directed agents, and expanding global adoption. With validated biomarkers, established diagnostic–therapeutic pairing, and multiple late-stage pipeline candidates, PSMA remains the most commercially mature and widely utilized target, reinforcing its position as the highest-revenue segment in the radioligand therapy market.

Radioligand Therapy Market, By Indication

Prostate cancer represents the largest share of the radioligand therapy market. This is driven by the high global burden of advanced prostate cancer, strong clinical success of PSMA-targeted therapies, and rapid adoption of treatments such as Lu-177 Pluvicto. With expanding diagnostic screening, increasing use in metastatic and earlier-line settings, and a robust pipeline of next-generation prostate cancer radioligands, this indication continues to generate the highest demand and commercial revenue in the RLT market.

Radioligand Therapy Market, By End user

As of 2024, tertiary care academic and comprehensive cancer centers account for the largest share of the radioligand therapy market by end user and are expected to maintain this lead through 2025. Their dominance is driven by advanced nuclear medicine infrastructure, multidisciplinary oncology teams, and the capacity to manage complex RLT workflows. These centers are also primary sites for clinical trials, early adoption of novel radiopharmaceuticals, and high-volume treatment of metastatic cancers, reinforcing their position as the highest-utilizing end-user segment in the radioligand therapy market.

REGION

Asia Pacific to be fastest-growing region in global pharmaceutical contract manufacturing market during forecast period

he Asia Pacific radioligand therapy (RLT) market is projected to grow at the fastest rate during the forecast period, driven by rising adoption of nuclear medicine, expanding theranostics programs, and increasing availability of PET/CT and SPECT imaging infrastructure. Countries such as China, Japan, South Korea, India, and Australia are investing in isotope production, cyclotrons, and GMP radiopharmaceutical facilities to support both clinical use and RLT manufacturing. Growing prostate and neuroendocrine cancer incidence, strong government backing for precision oncology, and the expansion of specialized cancer centers are accelerating regional demand. These factors collectively position Asia Pacific as the fastest-growing region in the global RLT marke

radioligand-therapy-rlt-market Region

radioligand-therapy-rlt-market: COMPANY EVALUATION MATRIX

In the radioligand therapy market matrix, Novartis (Star) leads with the strongest market share, driven by its approved products Pluvicto and Lutathera, global manufacturing network, and established theranostics model. ITM Isotope Technologies (Emerging Leader) is gaining momentum through expanded Lutetium-177 and Actinium-225 production and increasing partnerships with RLT developers. While Novartis dominates through scale and commercialization strength, ITM shows clear potential to advance toward the leaders quadrant as isotope demand and radioligand pipelines grow.

radioligand-therapy-rlt-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 2.36 Billion
Market Forecast in 2035 (Value) USD 10.92 Billion
Growth Rate CAGR of 13.2% from 2025-2030
Years Considered 2023-2035
Base Year 2024
Forecast Period 2025-2035
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product :
    • Lutetium-177 vipivotide tetraxetan (Pluvicto)
    • Lutetium-177 dotatate (Lutathera)
    • Radium-223 dichloride (Xofigo)
    • [Lu-177]-PNT2002
    • 225Ac-PSMA-617
    • FPI-2265
    • I-131-1095
    • TLX591 (177Lu rosopatamab tetraxetan)
    • AlphaMedix (²²Pb-DOTAMTATE)
    • 67Cu-SAR-bisPSMA
    • and other products.
  • By Target:
    • Prostate-Specific Membrane Antigen (PSMA)
    • Somatostatin Receptor (SSTR)
    • and other targets.
  • By Indications:
    • Prostate cancer
    • Neuroendocrine tumor
    • Others indications
  • By End users :
    • Tertiary Care Academic / Comprehensive Cancer centers
    • Specialized Nuclear Medicine Centers
    • and other end users.
Regions Covered North America, Asia Pacific, Europe, South America, Middle East and Africa

WHAT IS IN IT FOR YOU: radioligand-therapy-rlt-market REPORT CONTENT GUIDE

radioligand-therapy-rlt-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Inclusion of novel targets Addition of emerging targets beyond PSMA and SSTR Highlights innovation opportunities and early-mover advantages
Regulatory & reimbursement insights Addition of approval timelines, pricing, and reimbursement status Strengthens business continuity planning

RECENT DEVELOPMENTS

  • MArch 2025 : Novartis AG received FDA approval for Pluvicto, indicated for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) therapy.
  • April 2024 : Novartis AG received FDA approval for Lutathera as the first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors.
  • March 2024 : Bayer AG and PanThera entered into an agreement to supply starting material for next-gen radiopharmaceuticals.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
31
2
RESEARCH METHODOLOGY
 
 
 
35
3
EXECUTIVE SUMMARY
 
 
 
49
4
PREMIUM INSIGHTS
 
 
 
55
5
MARKET OVERVIEW
Rising demand for radioligand therapies driven by regulatory approvals and technological advancements.
 
 
 
61
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS
 
 
 
 
5.2.1.2
MANUFACTURING SCALE-UP OF LU-177
 
 
 
 
5.2.1.3
RISING ADOPTION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND SOMATOSTATIN RECEPTOR PET IMAGING
 
 
 
 
5.2.1.4
EXPANDING REIMBURSEMENT COVERAGE
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
ISOTOPE SUPPLY SCARCITY
 
 
 
 
5.2.2.2
STRINGENT REGULATORY REQUIREMENTS
 
 
 
 
5.2.2.3
LOGISTICAL HURDLES AND HALF-LIFE CONSTRAINTS
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
ADVANCEMENTS IN ALPHA THERAPIES
 
 
 
 
5.2.3.2
EXPANSION OF RADIOLIGAND THERAPY INTO EARLIER-LINE AND ADJUVANT SETTINGS
 
 
 
 
5.2.3.3
COMBINATION REGIMENS INTEGRATING RADIOLIGAND THERAPY
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
REACTOR OUTAGES AND GEOPOLITICAL RISKS
 
 
 
 
5.2.4.2
GROWING COMPETITION FROM ALTERNATIVE MODALITIES
 
 
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
5.4
PRICING ANALYSIS
 
 
 
 
 
 
5.4.1
INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
 
 
 
 
5.4.2
INDICATIVE PRICING ANALYSIS, BY REGION
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.6
ECOSYSTEM ANALYSIS
 
 
 
 
 
5.7
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
5.8
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.8.1
KEY TECHNOLOGIES
 
 
 
 
 
5.8.1.1
BETA-EMITTING THERAPEUTIC RADIONUCLIDES
 
 
 
 
5.8.1.2
ALPHA-EMITTING THERAPEUTIC RADIONUCLIDES
 
 
 
 
5.8.1.3
TARGETING LIGANDS
 
 
 
 
5.8.1.4
MONOCLONAL ANTIBODY-DIRECTED RADIOTHERAPEUTICS
 
 
 
5.8.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
5.8.2.1
SPECT/CT AND PET/CT
 
 
 
 
5.8.2.2
ALTERNATIVE ISOTOPES
 
 
 
5.8.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
5.8.3.1
ANTIBODY DRUG CONJUGATES
 
 
 
 
5.8.3.2
BISPECIFIC ANTIBODIES
 
 
5.9
KEY CONFERENCES AND EVENTS, 2025–2027
 
 
 
 
5.10
REGULATORY LANDSCAPE
 
 
 
 
 
5.10.1
REGULATORY ANALYSIS
 
 
 
 
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
5.11
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.11.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.11.2
BARGAINING POWER OF BUYERS
 
 
 
 
5.11.3
THREAT OF NEW ENTRANTS
 
 
 
 
5.11.4
THREAT OF SUBSTITUTES
 
 
 
 
5.11.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.12
KEY STAKEHOLDERS AND BUYING PROCESS
 
 
 
 
 
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.12.2
BUYING CRITERIA
 
 
 
5.13
MACROECONOMICS INDICATORS
 
 
 
 
 
5.13.1
HEALTHCARE EXPENDITURE TRENDS
 
 
 
 
5.13.2
GLOBAL CANCER BURDEN
 
 
 
5.14
PIPELINE ANALYSIS
 
 
 
 
5.15
UNMET NEEDS AND WHITE SPACES
 
 
 
 
5.16
IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET
 
 
 
 
 
 
5.16.1
INTRODUCTION
 
 
 
 
5.16.2
MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS
 
 
 
 
5.16.3
AI USE CASES
 
 
 
5.17
IMPACT OF 2025 US TARIFF
 
 
 
 
 
 
5.17.1
INTRODUCTION
 
 
 
 
5.17.2
KEY TARIFF RATES
 
 
 
 
5.17.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.17.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
5.17.4.1
US
 
 
 
 
5.17.4.2
EUROPE
 
 
 
 
5.17.4.3
ASIA PACIFIC
 
 
 
 
5.17.4.4
REST OF THE WORLD
 
 
 
5.17.5
IMPACT ON MANUFACTURING INDUSTRY
 
 
6
RADIOLIGAND THERAPY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 78 Data Tables
 
 
 
97
 
6.1
INTRODUCTION
 
 
 
 
6.2
LUTETIUM-177 VIPIVOTIDE TETRAXETAN
 
 
 
 
 
6.2.1
BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH
 
 
 
6.3
LUTETIUM-177 DOTATATE
 
 
 
 
 
6.3.1
INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET
 
 
 
6.4
RADIUM-223 DICHLORIDE
 
 
 
 
 
6.4.1
INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH
 
 
 
6.5
LU-177 PNT2002
 
 
 
 
 
6.5.1
STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH
 
 
 
6.6
²²5AC-PSMA-617
 
 
 
 
 
6.6.1
POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH
 
 
 
6.7
FPI-2265
 
 
 
 
 
6.7.1
EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH
 
 
 
6.8
I-131-1095
 
 
 
 
 
6.8.1
FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH
 
 
 
6.9
TLX591
 
 
 
 
 
6.9.1
SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET
 
 
 
6.10
ALPHAMEDIX ( ²¹²PB-DOTAMTATE)
 
 
 
 
 
6.10.1
ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH
 
 
 
6.11
67CU-SAR-BISPSMA
 
 
 
 
 
6.11.1
ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH
 
 
 
6.12
OTHER PRODUCTS
 
 
 
7
RADIOLIGAND THERAPY MARKET, BY TARGET
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
 
 
 
136
 
7.1
INTRODUCTION
 
 
 
 
7.2
PROSTATE-SPECIFIC MEMBRANE ANTIGEN
 
 
 
 
 
7.2.1
STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH
 
 
 
7.3
SOMATOSTATIN RECEPTOR
 
 
 
 
 
7.3.1
PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH
 
 
 
7.4
OTHER TARGETS
 
 
 
8
RADIOLIGAND THERAPY MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
 
 
 
148
 
8.1
INTRODUCTION
 
 
 
 
8.2
PROSTATE CANCER
 
 
 
 
 
8.2.1
EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH
 
 
 
8.3
NEUROENDOCRINE TUMORS
 
 
 
 
 
8.3.1
REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH
 
 
 
8.4
OTHER INDICATIONS
 
 
 
9
RADIOLIGAND THERAPY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 22 Data Tables
 
 
 
160
 
9.1
INTRODUCTION
 
 
 
 
9.2
TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS
 
 
 
 
 
9.2.1
ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH
 
 
 
9.3
SPECIALIZED NUCLEAR MEDICINE CENTERS
 
 
 
 
 
9.3.1
HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH
 
 
 
9.4
OTHER END USERS
 
 
 
10
RADIOLIGAND THERAPY MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 125 Data Tables.
 
 
 
173
 
10.1
INTRODUCTION
 
 
 
 
10.2
NORTH AMERICA
 
 
 
 
 
10.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
10.2.2
US
 
 
 
 
 
10.2.2.1
ROBUST ECOSYSTEM OF BIOTECH INNOVATION AND STRONG ACADEMIC-INDUSTRY COLLABORATION TO SPUR GROWTH.
 
 
 
10.2.3
CANADA
 
 
 
 
 
10.2.3.1
GROWING CLINICAL TRIAL MOMENTUM TO DRIVE MARKET
 
 
10.3
EUROPE
 
 
 
 
 
10.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
10.3.2
GERMANY
 
 
 
 
 
10.3.2.1
STRONG CLINICAL ADVANCEMENTS AND ACTIVE INDUSTRY PARTNERSHIPS TO FOSTER GROWTH.
 
 
 
10.3.3
UK
 
 
 
 
 
10.3.3.1
GROWING EFFORTS FOR DECENTRALIZED ACCESS AND INNOVATIONS TO BOOST MARKET
 
 
 
10.3.4
FRANCE
 
 
 
 
 
10.3.4.1
STRONG NUCLEAR MEDICINE MANUFACTURING AND ISOTOPE SUPPLY FOUNDATION TO BOLSTER GROWTH
 
 
 
10.3.5
ITALY
 
 
 
 
 
10.3.5.1
RISING PRECLINICAL EXPLORATION AND EARLY DISCOVERY STAGES TO STIMULATE GROWTH
 
 
 
10.3.6
SPAIN
 
 
 
 
 
10.3.6.1
ESTABLISHED NUCLEAR-MEDICINE DEPARTMENTS AND AUTHORIZED RADIOPHARMACY FRAMEWORKS TO AID GROWTH
 
 
 
10.3.7
REST OF EUROPE
 
 
 
10.4
ASIA PACIFIC
 
 
 
 
 
10.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
10.4.2
CHINA
 
 
 
 
 
10.4.2.1
FAVORABLE REGULATORY REFORMS AND EXPANDING HOSPITAL-BASED NUCLEAR MEDICINE CAPABILITIES TO AMPLIFY GROWTH
 
 
 
10.4.3
JAPAN
 
 
 
 
 
10.4.3.1
ACADEMIC EXCELLENCE, MANUFACTURING EXPANSION, AND SUPPORTIVE REGULATION TO CONTRIBUTE TO GROWTH
 
 
 
10.4.4
INDIA
 
 
 
 
 
10.4.4.1
LOWER TRIAL COSTS AND SKILLED MEDICAL PROFESSIONALS TO ACCELERATE GROWTH
 
 
 
10.4.5
SOUTH KOREA
 
 
 
 
 
10.4.5.1
GROWING EMPHASIS ON NUCLEAR MEDICINE INNOVATION TO PROPEL MARKET
 
 
 
10.4.6
AUSTRALIA
 
 
 
 
 
10.4.6.1
NEED TO MAINTAIN HIGH STANDARDS OF QUALITY, COMPLIANCE, AND INNOVATION TO FACILITATE GROWTH
 
 
 
10.4.7
REST OF ASIA PACIFIC
 
 
 
10.5
LATIN AMERICA
 
 
 
 
 
10.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
10.5.2
BRAZIL
 
 
 
 
 
10.5.2.1
FAVORABLE EDUCATIONAL INITIATIVES AND EXPANDING BIOPHARMA INFRASTRUCTURE TO PROMOTE GROWTH
 
 
 
10.5.3
MEXICO
 
 
 
 
 
10.5.3.1
GROWING CYCLOTRON CAPACITY TO FUEL MARKET
 
 
 
10.5.4
REST OF LATIN AMERICA
 
 
 
10.6
MIDDLE EAST
 
 
 
 
 
10.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
 
 
 
 
10.6.2
GCC COUNTRIES
 
 
 
 
10.6.3
SAUDI ARABIA
 
 
 
 
 
10.6.3.1
GROWING INITIATIVES FOR HEALTHCARE AND LIFE SCIENCES SECTORS TO DRIVE MARKET
 
 
 
10.6.4
UAE
 
 
 
 
 
10.6.4.1
EMERGING BIOTECHNOLOGY SECTOR TO INTENSIFY GROWTH
 
 
 
10.6.5
REST OF GCC COUNTRIES
 
 
 
 
10.6.6
REST OF MIDDLE EAST
 
 
 
10.7
AFRICA
 
 
 
 
 
10.7.1
ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH
 
 
 
 
10.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
 
 
11
COMPETITIVE LANDSCAPE
Discover strategic maneuvers propelling top players to dominate market share and valuations by 2030.
 
 
 
242
 
11.1
INTRODUCTION
 
 
 
 
11.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
11.3
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
 
 
 
 
11.4
REVENUE ANALYSIS, 2028–2030
 
 
 
 
 
11.5
MARKET SHARE ANALYSIS, 2030
 
 
 
 
 
11.6
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
11.7
BRAND/PRODUCT COMPARISON
 
 
 
 
 
11.8
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
11.8.1
STARS
 
 
 
 
11.8.2
EMERGING LEADERS
 
 
 
 
11.8.3
PERVASIVE PLAYERS
 
 
 
 
11.8.4
PARTICIPANTS
 
 
 
 
11.8.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
11.8.5.1
REGION FOOTPRINT
 
 
 
 
11.8.5.2
TARGET FOOTPRINT
 
 
 
 
11.8.5.3
INDICATION FOOTPRINT
 
 
11.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
11.9.1
PROGRESSIVE COMPANIES
 
 
 
 
11.9.2
RESPONSIVE COMPANIES
 
 
 
 
11.9.3
DYNAMIC COMPANIES
 
 
 
 
11.9.4
STARTING BLOCKS
 
 
 
 
11.9.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
11.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
11.9.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
11.10
COMPETITIVE SCENARIO
 
 
 
 
 
11.10.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
11.10.2
DEALS
 
 
 
 
11.10.3
EXPANSIONS
 
 
12
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
260
 
12.1
KEY PLAYERS
 
 
 
 
 
12.1.1
NOVARTIS AG
 
 
 
 
 
12.1.1.1
BUSINESS OVERVIEW
 
 
 
 
12.1.1.2
PRODUCTS OFFERED
 
 
 
 
12.1.1.3
PRODUCTS IN PIPELINE
 
 
 
 
12.1.1.4
RECENT DEVELOPMENTS
 
 
 
 
12.1.1.5
MNM VIEW
 
 
 
12.1.2
BAYER AG
 
 
 
 
12.1.3
CURIUM US LLC
 
 
 
 
12.1.4
ELI LILLY AND COMPANY
 
 
 
 
12.1.5
ASTRAZENECA
 
 
 
 
12.1.6
PROGENICS PHARMACEUTICALS INC. (LANTHEUS)
 
 
 
 
12.1.7
ARICEUM THERAPEUTICS
 
 
 
 
12.1.8
TELIX PHARMACEUTICALS
 
 
 
 
12.1.9
ITM ISOTOPE TECHNOLOGIES
 
 
 
 
12.1.10
CONVERGENT THERAPEUTICS, INC.
 
 
 
 
12.1.11
ORANO SA
 
 
 
 
12.1.12
ACTINIUM PHARMACEUTICALS, INC.
 
 
 
 
12.1.13
PERSPECTIVE THERAPEUTICS, INC.
 
 
 
 
12.1.14
CLARITY PHARMACEUTICALS
 
 
 
 
12.1.15
RADIOPHARM THERANOSTICS LTD.
 
 
 
12.2
OTHER PLAYERS
 
 
 
 
 
12.2.1
ALPHA 9 ONCOLOGY
 
 
 
 
12.2.2
RATIO THERAPEUTICS
 
 
 
 
12.2.3
NORIA THERAPEUTICS
 
 
 
 
12.2.4
PRECIRIX
 
 
 
 
12.2.5
SOFIE
 
 
 
 
12.2.6
ECKERT & ZIEGLER RADIOPHARMA
 
 
 
 
12.2.7
NORTHSTAR MEDICAL RADIOISOTOPES, LLC
 
 
 
 
12.2.8
IRE- IRE ELIT
 
 
 
 
12.2.9
BWXT MEDICAL LTD.
 
 
 
 
12.2.10
NTP RADIOISOTOPES
 
 
13
APPENDIX
 
 
 
305
 
13.1
DISCUSSION GUIDE
 
 
 
 
13.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
13.3
CUSTOMIZATION OPTIONS
 
 
 
 
13.4
RELATED REPORTS
 
 
 
 
13.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS
 
 
 
 
TABLE 2
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
TABLE 3
RADIOLIGAND THERAPY MARKET: RISK ANALYSIS
 
 
 
 
TABLE 4
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
TABLE 5
RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
 
 
 
 
TABLE 6
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024
 
 
 
 
TABLE 7
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY REGION, 2024
 
 
 
 
TABLE 8
RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
TABLE 9
RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS, 2025–2027
 
 
 
 
TABLE 10
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 11
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 12
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 13
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 14
RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
TABLE 15
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS (%)
 
 
 
 
TABLE 16
KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER
 
 
 
 
TABLE 17
HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP)
 
 
 
 
TABLE 18
US: CANCER INCIDENCE, BY STATE, 2024
 
 
 
 
TABLE 19
RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025–2032
 
 
 
 
TABLE 20
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
TABLE 21
RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 22
RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 23
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 24
EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 25
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 26
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 27
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 28
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 29
RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 30
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 31
EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 32
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 33
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 34
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 35
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 36
RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 37
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 38
EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 39
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 40
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 41
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 42
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 43
RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 44
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 45
EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 46
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 47
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 48
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 49
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 50
RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 51
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 52
EUROPE: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 53
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 54
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617,0 BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 55
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 56
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²²5AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 57
RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 58
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 59
EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 60
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 61
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 62
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 63
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 64
RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 65
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 66
EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 67
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 68
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 69
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 70
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 71
RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 72
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 73
EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 74
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 75
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 76
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 77
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 78
RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 79
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 80
EUROPE: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 81
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 82
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 83
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 84
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 85
RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 86
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 87
EUROPE: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 88
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 89
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 90
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 91
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 92
RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 93
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 94
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 95
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 96
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 97
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 98
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 99
RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 100
RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 101
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 102
EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 103
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 104
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 105
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 106
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 107
RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 108
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 109
EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 110
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 111
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 112
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 113
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 114
RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 115
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 116
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 117
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 118
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 119
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 120
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 121
RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 122
RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 123
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 124
EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 125
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 126
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 127
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 128
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 129
RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 130
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 131
EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 132
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 133
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 134
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 135
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 136
RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 137
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 138
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 139
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 140
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 141
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 142
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 143
RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 144
RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 145
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 146
EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 147
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 148
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 149
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 150
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 151
RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 152
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 153
EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 154
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 155
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 156
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 157
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 158
RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 159
NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 160
EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 161
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 162
LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 163
MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 164
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 165
RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 166
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 167
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 168
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 169
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 170
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 171
NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 172
US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 173
US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 174
US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 175
US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 176
CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 177
CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 178
CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 179
CANADA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 180
EUROPE: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 181
EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 182
EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 183
EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 184
EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 185
EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 186
GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 187
GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 188
GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 189
GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 190
UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 191
UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 192
UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 193
UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 194
FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 195
FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 196
FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 197
FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 198
ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 199
ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 200
ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 201
ITALY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 202
SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 203
SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 204
SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 205
SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 206
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 207
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 208
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 209
REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 210
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 211
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 212
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 213
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 214
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 215
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 216
CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 217
CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 218
CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 219
CHINA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 220
JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 221
JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 222
JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 223
JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 224
INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 225
INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 226
INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 227
INDIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 228
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 229
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 230
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 231
SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 232
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 233
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 234
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 235
AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 236
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 237
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 238
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 239
REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 240
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 241
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 242
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 243
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 244
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 245
LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 246
BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 247
BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 248
BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 249
BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 250
MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 251
MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 252
MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 253
MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 254
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 255
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 256
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 257
REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 258
MIDDLE EAST: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 259
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 260
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 261
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 262
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 263
MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 264
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 265
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 266
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 267
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 268
GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 269
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 270
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 271
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 272
SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 273
UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 274
UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 275
UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 276
UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 277
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 278
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 279
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 280
REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 281
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 282
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 283
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 284
REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 285
AFRICA: KEY MACROECONOMIC INDICATORS
 
 
 
 
TABLE 286
AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 287
AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 288
AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 289
AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)
 
 
 
 
TABLE 290
OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023–2025
 
 
 
 
TABLE 291
RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION
 
 
 
 
TABLE 292
RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 293
RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT
 
 
 
 
TABLE 294
RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT
 
 
 
 
TABLE 295
RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
TABLE 296
RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
TABLE 297
RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 298
RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 299
RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 300
NOVARTIS AG: COMPANY OVERVIEW
 
 
 
 
TABLE 301
NOVARTIS AG: PRODUCTS OFFERED
 
 
 
 
TABLE 302
NOVARTIS AG: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 303
NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 304
NOVARTIS AG: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 305
NOVARTIS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 306
BAYER AG: COMPANY OVERVIEW
 
 
 
 
TABLE 307
BAYER AG: PRODUCTS OFFERED
 
 
 
 
TABLE 308
BAYER AG: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 309
BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 310
CURIUM US LLC: COMPANY OVERVIEW
 
 
 
 
TABLE 311
CURIUM US LLC: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 312
CURIUM US LLC: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 313
ELI LILLY AND COMPANY: COMPANY OVERVIEW
 
 
 
 
TABLE 314
ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 315
ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– AUGUST 2025
 
 
 
 
TABLE 316
ELI LILLY AND COMPANY: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 317
ASTRAZENECA: COMPANY OVERVIEW
 
 
 
 
TABLE 318
ASTRAZENECA: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 319
ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 320
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW
 
 
 
 
TABLE 321
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE
 
 
 
 
TABLE 322
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 323
ARICEUM THERAPEUTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 324
ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 325
ARICEUM THERAPEUTICS: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 326
TELIX PHARMACEUTICALS: COMPANY OVERVIEW
 
 
 
 
TABLE 327
TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 328
TELIX PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 329
TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 330
TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 331
ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW
 
 
 
 
TABLE 332
ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED
 
 
 
 
TABLE 333
ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 334
ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 335
CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 336
CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 337
CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 338
CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 339
ORANO SA: COMPANY OVERVIEW
 
 
 
 
TABLE 340
ORANO SA: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 341
ORANO SA: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 342
ORANO SA: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 343
ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 344
ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 345
ACTINIUM PHARMACEUTICALS, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 346
ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 347
PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 348
PERSPECTIVE THERAPEUTICS, INC.: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 349
PERSPECTIVE THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 350
CLARITY PHARMACEUTICALS: COMPANY OVERVIEW
 
 
 
 
TABLE 351
CLARITY PHARMACEUTICALS: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 352
CLARITY PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 353
CLARITY PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 354
RADIOPHARM THERANOSTICS LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 355
RADIOPHARM THERANOSTICS LTD.: PRODUCTS IN PIPELINE
 
 
 
 
TABLE 356
RADIOPHARM THERANOSTICS LTD.: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 357
ALPHA 9 ONCOLOGY: COMPANY OVERVIEW
 
 
 
 
TABLE 358
RATIO THERAPEUTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 359
NORIA THERAPEUTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 360
PRECIRIX: COMPANY OVERVIEW
 
 
 
 
TABLE 361
SOFIE: COMPANY OVERVIEW
 
 
 
 
TABLE 362
ECKERT & ZIEGLER RADIOPHARMA: COMPANY OVERVIEW
 
 
 
 
TABLE 363
NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY OVERVIEW
 
 
 
 
TABLE 364
IRE- IRE ELIT: COMPANY OVERVIEW
 
 
 
 
TABLE 365
BWXT MEDICAL LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 366
NTP RADIOISOTOPES: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE
 
 
 
 
FIGURE 2
RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED
 
 
 
 
FIGURE 3
RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN
 
 
 
 
FIGURE 4
RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES
 
 
 
 
FIGURE 5
RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
FIGURE 6
RADIOLIGAND THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
 
 
 
 
FIGURE 7
COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030
 
 
 
 
FIGURE 8
REVENUE SHARE ANALYSIS OF NOVARTIS, 2024
 
 
 
 
FIGURE 9
RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES
 
 
 
 
FIGURE 10
RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH
 
 
 
 
FIGURE 11
RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS
 
 
 
 
FIGURE 12
RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION
 
 
 
 
FIGURE 13
RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
 
 
 
 
FIGURE 14
RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION)
 
 
 
 
FIGURE 15
RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION)
 
 
 
 
FIGURE 16
RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION)
 
 
 
 
FIGURE 17
RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)
 
 
 
 
FIGURE 18
GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET
 
 
 
 
FIGURE 19
INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS TO DRIVE MARKET
 
 
 
 
FIGURE 20
LUTETIUM-177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024
 
 
 
 
FIGURE 21
CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
FIGURE 22
DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
FIGURE 23
RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
FIGURE 24
NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET
 
 
 
 
FIGURE 25
INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024
 
 
 
 
FIGURE 26
INDICATIVE PRICING ANALYSIS, BY REGION, 2024
 
 
 
 
FIGURE 27
RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
FIGURE 28
RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
FIGURE 29
RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO, 2023–2024
 
 
 
 
FIGURE 30
RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
FIGURE 31
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS
 
 
 
 
FIGURE 32
KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER
 
 
 
 
FIGURE 33
RADIOLIGAND THERAPY MARKET: AI USE CASES
 
 
 
 
FIGURE 34
NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT
 
 
 
 
FIGURE 35
ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT
 
 
 
 
FIGURE 36
RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION)
 
 
 
 
FIGURE 37
RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030
 
 
 
 
FIGURE 38
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 39
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 40
RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
FIGURE 41
RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
FIGURE 42
RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT
 
 
 
 
FIGURE 43
RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
FIGURE 44
NOVARTIS AG: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 45
BAYER AG: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 46
ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 47
ASTRAZENECA: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 48
PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 49
TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 50
ORANO SA: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 51
ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
 
 
 
 
FIGURE 52
CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
 
 
 
 

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global radioligand therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the radioligand therapy market. The secondary sources used for this study include World Health Organization (WHO), National Institutes of Health (NIH), National Cancer Institute (NCI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Centers for Drug Evaluation and Research (CDER), International Society for Pharmaceutical Engineering (ISPE), Innovative Medicines Initiative (IMI), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM), PubMed, National Center for Biotechnology Information (NCBI), International Trade Centre (ITC), Press Releases, Company Websites, and Magazines & Proprietary Databases. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis.

Primary Research

A comprehensive primary research was undertaken following an initial assessment of the global radioligand therapy market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

The following is a breakdown of the primary respondents:

Radioligand Therapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the radioligand therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the radioligand therapy market was generated.
  • The revenues generated from their radioligand therapy product have been determined through annual reports and secondary sources (including paid databases)
  • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Radioligand Therapy Market : Top-Down and Bottom-Up Approach

Radioligand Therapy Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Radioligand therapy (RLT) is a form of precision oncology that delivers targeted radiation to cancer cells while minimizing damage to healthy cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing for precise radiation delivery while minimizing damage to surrounding healthy tissues.

Stakeholders

  • Pharmaceutical Companies
  • National and Regional Research Boards & Organizations
  • Research & Development Companies
  • Contract Research Organizations (CROs)
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Development & Manufacturing Organizations (CRDMOs)
  • Medical Device Companies
  • Biotechnology Companies
  • Research Laboratories & Academic Institutes
  • Market Research & Consulting Firms
  • Regulatory Bodies

Report Objectives

  • To define, describe, and forecast the radioligand therapy market based on product, target, indication, end user, and region
  • To provide detailed information on the significant factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the radioligand therapy market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments concerning six regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global radioligand therapy market and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as product approvals & launches, expansions, agreements, and collaborations in the radioligand therapy market
  • To benchmark players within the radioligand therapy market using the company evaluation matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Radioligand Therapy (RLT) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Radioligand Therapy (RLT) Market

DMCA.com Protection Status